26 February 2021
EMA/PDCO/138740/2021
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 23-26 February 2021

Chair: Koenraad Norga – Vice-Chair: Sabine Scherer

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

Due to restricted involvement, the Chair Koenraad Norga was replaced by the Vice-chair Sabine Scherer for the voting on agenda topic 2.3.1, 3.3.18 and 3.3.21.

1.2. Adoption of agenda

PDCO agenda for 23-26 February 2021

The agenda of the PDCO meeting 23-26 February 2021 was adopted.

1.3. Adoption of the minutes

PDCO minutes for 26-29 January 2021

The minutes of the PDCO meeting 26-29 January 2021 were adopted and will be published on the EMA website.

2. Opinions

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Dupilumab - EMEA-001501-PIP07-20

sanofi-aventis recherche & développement; Treatment of chronic spontaneous urticaria

Day 120 opinion

Dermatology

Summary of committee discussion:

The Committee adopted a positive opinion, including a deferral and a waiver in a subset of children on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2.1.2. Ritlecitinib - EMEA-002451-PIP01-18

Pfizer Europe MA EEIG; Alopecia areata

Day 120 opinion

Dermatology

Summary of committee discussion:

The committee re-discussed the paediatric plan taking into account the Applicant's additional clarifications and information.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO adopted a positive opinion for ritlecitinib in the condition "treatment of alopecia areata".

2.1.3. Hydroxypropyl-β-cyclodextrin - Orphan - EMEA-002839-PIP01-20

Cyclo Therapeutics Inc; Niemann Pick disease type C / Treatment of Niemann Pick type C1 disease in children, adolescents and adults

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

During its plenary on 26 February 2021, the PDCO discussed the responses to the day 90 outstanding issues for the PIP proposal for Hydroxypropyl-β-cyclodextrin (HPβCD) administered intravenously for the treatment of the lysosomal storage disease Niemann Pick disease, type C.
The PDCO agreed that all issues have been addressed/clarified adequately by the applicant and the PIP Opinion has been amended as relevant. Therefore, a positive Opinion has been adopted by the PDCO.

2.1.4. Pioglitazone (hydrochloride) / Spironolactone / metformin (hydrochloride) - EMEA-002187-PIP01-17

Katholieke Universiteit Leuven (KUL) Research & Development; Treatment of polycystic ovary syndrome (PCOS) / Treatment of adolescent polycystic ovary syndrome (PCOS) in post-menarche adolescents <18 yrs and young adult women ≥18 yrs and <24.0 yrs

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The PDCO discussed the additional information provided by the applicant .
In conclusion, the PDCO adopted a positive opinion for the fixed-dose combination of metformin hydrochloride / pioglitazone hydrochloride / spironolactone for treatment of polycystic ovary syndrome in post-menarche adolescents (2 years post-menarche or above 14 years of age for girls with primary amenorrhea) and <18 years. A waiver was granted for boys from birth to less than 18 years and premenarcheal girls on the ground that the condition does not occur in the specified paediatric subsets and a waiver in a subset of post-menarcheal girls on the ground that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subsets.

2.1.5. Risankizumab - EMEA-001776-PIP05-20

AbbVie Ltd; Hidradenitis suppurativa

Day 120 opinion

Immunology-Rheumatology-Transplantation / Dermatology

Post-meeting note: The applicant withdrew the application 25/02/2021.

2.1.6. Adeno-associated virus, serotype 9 (AAV9)-based non-replicating, self-complementary recombinant vector containing an expression cassette for the human ASPA transgene (scAAV9-CB6-hASPAopt) - Orphan - EMEA-002779-PIP01-20

Aspa Therapeutics, Inc.; Treatment of Canavan disease

Day 120 opinion

Neurology

Summary of committee discussion:

The PDCO re-discussed this procedure at Day 120 during the February 2021 plenary meeting.
The PDCO agreed with the applicant’s proposal and adopted a positive opinion on a paediatric investigation plan with a deferral in a subset of patients in the condition of treatment of Canavan disease.

2.1.7. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride - Orphan - EMEA-002486-PIP03-20

Advenchen Laboratories, LLC.; Treatment of soft tissue sarcomas / Treatment of alveolar soft part sarcoma / Treatment of synovial sarcoma / Treatment of rhabdomyosarcoma

Day 120 opinion

Oncology

Post-meeting note: The applicant withdrew the application on 23/02/2021.

2.1.8. Surufatinib - EMEA-002750-PIP01-19

Hutchison MediPharma Ltd; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) and Treatment of malignant neoplasms of haematopoietic and lymphoid tissue

Day 120 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this procedure at Day 120 during the February 2021 plenary meeting.
Thus, the PDCO adopted a positive opinion on a paediatric investigation plan with a deferral in the conditions of treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) and treatment of malignant neoplasms of haematopoietic and lymphoid tissue.

2.1.9. Zilucoplan - EMEA-002747-PIP01-20

UCB Pharma SA; Treatment of myasthenia gravis

Day 120 opinion

Other / Neurology

Summary of committee discussion:

The PDCO adopted a positive opinion, including a deferral for completion of all studies in the PIP and a waiver for a subset of children on the grounds that clinical studies with zilucoplan cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset.

2.1.10. Chikungunya Virus Virus-Like Particle Vaccine - EMEA-002656-PIP01-19

Emergent Netherlands B.V.; Chikungunya disease

Day 120 opinion

Vaccines

Summary of committee discussion:

The PDCO discussed the responses of the applicant and was of the opinion that the proposal for development from birth could be acceptable, considering the burden of disease in the first months of life. It was also clarified that the applicant will pursue development in non-endemic areas also for the adult MA, and this approach was accepted at the latest scientific advice. The applicant also plans some studies in endemic areas as post-marketing commitment. All other issues remaining at day 90 were considered solved.
The PDCO agreed on a positive opinion on a PIP, covering development from birth to less than 18 years of age, and a deferral, for Chikungunya Virus Virus-Like Particle Vaccine.

2.1.11. Fluoride 18-labelled Prostate-Specific Membrane Antigen-1007 ([18F]PSMA-1007) - EMEA-002918-PIP01-20

ABX advanced biochemical compounds Biomedizinische Forschungsreagenzien GmbH; Visualisation of prostate specific membrane antigen in prostate cancer

Day 60 opinion

Diagnostic / Oncology

Summary of committee discussion:

The PDCO re-discussed this procedure at Day 60 during the February 2021 plenary meeting. The PDCO adopted a positive opinion on a product specific waiver for [18F]PSMA-1007 for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of visualisation of prostate specific membrane antigen in prostate cancer on the grounds that the condition for which the medicinal product is intended only occurs in the adult population.
The PDCO emphasises that the granting of a waiver for the conditions mentioned above should not prevent the applicant from considering development in the paediatric population in indications where there is a paediatric need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.12. Sutimlimab - Orphan - EMEA-002542-PIP03-20

Genzyme Europe B.V.; Treatment of Cold Agglutinin Disease

Day 60 opinion

Haematology-Hemostaseology

Summary of committee discussion:

The PDCO re-discussed this application in line with the outcome conclusions from D30. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for sutimlimab for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of cold agglutinin disease based on the ground that the disease does not occur in children. Since the most appropriate waiver ground is considered to be disease not occurring in the paediatric population, the possibility to apply this to all pharmaceutical forms and all routes of administrations was agreed to by

the applicant.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.13. Anti-IL-7Rα monoclonal antibody (S95011/ OSE-127) - EMEA-002930-PIP01-20

Les Laboratoires Servier; Treatment of Sjögren's syndrome

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO's view expressed at Day 30 was re-discussed and endorsed.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for anti-IL-7Rα monoclonal antibody (S95011 / OSE-127) for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of Sjögren's syndrome.

2.1.14. Anti-alpha-synuclein human monoclonal antibody - EMEA-002936-PIP01-20

H. Lundbeck A/S; Multiple System Atrophy / Parkinson's Disease

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for anti-(alpha-synuclein) human monoclonal antibody for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of "treatment of Parkinson's Disease" on the grounds that the specific medicinal product is likely to be ineffective and in the condition "treatment of multiple system atrophy" on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).
The PDCO emphasises that the granting of a waiver for the conditions mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.15. Oxygen / Argon - EMEA-002921-PIP01-20

Air Liquide Santé International; Treatment of acute ischaemic stroke

Day 60 opinion

Neurology

Summary of committee discussion:

Responses from the applicant were noted.
The PDCO re-discussed the condition and concluded on granting a waiver in the narrower condition of treatment of acute ischaemic stroke due to large intracranial vessel occlusion after thrombectomy for Argon / Oxygen for all subsets of the paediatric population (birth to less than 18 years of age on the grounds of a lack of significant therapeutic benefit because clinical studies in children would be unfeasible.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO identified sporadic paediatric cases of acute ischaemic stroke that may undergo mechanical thrombectomy as an unmet need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.16. Tavapadon - EMEA-002920-PIP01-20

Cerevel Therapeutics, LLC; Treatment of Parkinson's disease

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for tavapadon for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of Parkinson's disease on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.17. 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl) acetamide monohydrate - Orphan - EMEA-002923-PIP01-20

Constellation Pharmaceuticals Inc.; Treatment of myelofibrosis

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed product for all subsets of the paediatric

population (0 to 18 years of age) in the condition of treatment of myelofibrosis.

2.1.18. Encequidar - Orphan - EMEA-002913-PIP01-20

Athenex Inc.; Breast cancer, Soft tissue sarcoma / Breast cancer / Angiosarcoma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this application in line with the outcome conclusions from D30. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for encequidar for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of breast cancer and treatment of soft tissue sarcoma based on the ground of lack of efficacy. Since the most appropriate waiver ground for both conditions is considered to be lack of efficacy, the possibility to apply this to all pharmaceutical forms and all routes of administrations was agreed to by the applicant. The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.19. Ensartinib - EMEA-002937-PIP01-20

Xcovery Holdings, Inc.; Treatment of non-small-cell lung cancer

Day 60 opinion

Oncology

Summary of committee discussion:

The responses provided by the Applicant after D30 were noted.
In conclusion, the PDCO's views expressed at D30 were endorsed. The Committee agrees with the Applicant's request for a waiver and recommends granting a waiver for ensartinib for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of non-small-cell lung cancer based on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).
The applicant also agreed with the proposal to specify in the opinion that the product specific waiver referred to all pharmaceutical forms and all routes formulation.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.20. Humanised recombinant IgG4, Anti-PD-1 monoclonal antibody (CS1003) - EMEA-002939-PIP01-20

CStone Pharmaceuticals (Suzhou) CO., Ltd.; Treatment of hepatocellular carcinoma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this procedure at Day 60 during the February 2021 plenary meeting. The Committee confirmed all the conclusions reached at Day 30.
Therefore, the PDCO adopted a positive opinion on a product specific waiver for humanised recombinant IgG4, anti-PD-1 monoclonal antibody (CS1003) for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of hepatocellular carcinoma on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.
The PDCO emphasises that the granting of a waiver for the conditions mentioned above should not prevent the applicant from considering development in the paediatric population in indications where there is a paediatric need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.21. Nadofaragene firadenovec - EMEA-002376-PIP02-20

Ferring Pharmaceuticals A/S; Treatment of malignant bladder neoplasms

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this application in line with the outcome conclusions from D30. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for nadofaragene firadenovec for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of malignant bladder neoplasms based on the ground that the disease does not occur in children. Since the most appropriate waiver ground is considered to be disease not occurring in the paediatric population, the possibility to apply this to all pharmaceutical forms and all routes of administrations was agreed to by the applicant.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.22. Paclitaxel - Orphan - EMEA-002894-PIP01-20

Athenex Inc.; Breast cancer / Soft tissue sarcoma / Breast cancer / Angiosarcoma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this application in line with the outcome conclusions from D30. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for paclitaxel for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of soft tissue sarcoma based on the ground of lack of efficacy. Since the most appropriate waiver ground is considered to be lack of efficacy, the possibility to apply this to all pharmaceutical forms and all routes of administrations was agreed to by the applicant.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.23. Sabatolimab - EMEA-002931-PIP01-20

Novartis Europharm; Treatment of myelodysplastic syndrome

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed the requested waiver for sabatolimab based on the responses provided by the Applicant after D30.
In conclusion, the PDCO recommended granting a waiver for sabatolimab for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of myelodysplastic syndrome based on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO identified acute myeloid leukaemia as an unmet need that may be covered by the treatment with sabatolimab. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.
The applicant is also reminded that Applicants are welcome to submit their PIP applications during or even before initial PK studies in adults as that would ensure an early dialogue between the Applicant and the Paediatric Committee.

2.1.24. Sintilimab - EMEA-002919-PIP01-20

Eli Lilly and Company Limited; Lung malignant neoplasm

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this application in line with the outcome conclusions from D30. Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for sintilimab for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of lung cancer. Since the most appropriate waiver ground is considered to be disease not occurring in the paediatric population, the possibility to apply this to all pharmaceutical forms and all routes of administrations was agreed to by the applicant.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.25. Talazoparib - EMEA-002066-PIP02-20

Pfizer Europe MA EEIG; Treatment of prostate malignant neoplasms / Treatment of breast malignant neoplasms

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed this procedure at Day 60 during the February 2021 plenary meeting. The PDCO adopted a positive opinion on a product specific waiver for talazoparib for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of treatment of breast malignant neoplasms and of treatment of prostate malignant neoplasms on the grounds that the conditions for which the medicinal product is intended only occur in the adult population.
The PDCO emphasises that the granting of a waiver for the conditions mentioned above should not prevent the applicant from considering development in the paediatric population in indications where there is a paediatric need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

2.2.1. Sofosbuvir / Velpatasvir - EMEA-C-001646-PIP01-14-M02

Gilead Sciences Ireland UC; Treatment of chronic hepatitis C

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-001646-PIP01-14-M02

The PDCO adopted on 25 February 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision P/0150/2018 of 18 May 2018.

2.2.2. Bilastine - EMEA-C1-000347-PIP02-16-M02

FAES FARMA, S.A.; Treatment of allergic conjunctivitis

Day 60 letter

Ophthalmology / Pneumology – Allergology

Summary of committee discussion:

The PDCO re-discussed the initiation of Study 1 (BOFT-0520-PED).

Based on further justification provided by the Applicant on 8 February 2021 the Committee considered that Study 1 initiation and Study 2 are compliant with the latest Agency's Decision P/0466/2020 of 1 December 2020.

The PDCO finalised this partially completed compliance procedure on 25 February 2021.

2.2.3. Cerliponase alfa - EMEA-C-001362-PIP01-12-M03

BioMarin International Limited; Treatment of Neuronal Ceroid Lipofuscinosis Type 2 (NCL2)

Day 60 opinion

Other / Neurology

Summary of committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-001362-PIP01-12-M02
- EMEA-C2-001362-PIP01-12-M03

The PDCO adopted on 25 February 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision P/0248/2016 of 5 September 2016.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Ambrisentan - Orphan - EMEA-000434-PIP01-08-M08

Glaxo Group Limited; Pulmonary Arterial Hypertension / Treatment of Pulmonary Arterial Hypertension

Day 60 opinion

Action: For adoption

Cardiovascular Diseases

Post-meeting note: The company withdrew the application on 25/02/2021.

2.3.2. Azilsartan medoxomil - EMEA-000237-PIP01-08-M09

Takeda Development Centre Europe Ltd; Treatment of hypertension / Essential (primary) hypertension / Secondary hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0034/2019 of 29 January 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Landiolol (hydrochloride) - EMEA-001150-PIP02-13-M04

AOP Orphan Pharmaceuticals AG; Treatment of supraventricular arrythmias

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

The PDCO discussed the responses of the applicant to the issues raised at day 30 in February 2021.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0273/2018 of 14/8/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. Bimekizumab - EMEA-002189-PIP01-17-M02

UCB Biopharma SRL; Treatment of psoriasis

Day 60 opinion

Dermatology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0375/2019 of 4 December 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Gadopiclenol - EMEA-001949-PIP01-16-M04

Guerbet; Diagnostic / MRI in brain (intracranial), spine and associated tissues to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity

Day 60 opinion

Diagnostic

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0055/2019 of 11 February 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Gadopiclenol - EMEA-001949-PIP02-18-M01

Guerbet; Diagnostic / Detection and visualization of disorders or lesions with suspected abnormal vascularity in various body regions

Day 60 opinion

Diagnostic

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0145/2019 of 17 April 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Ethinyl estradiol / Dienogest - EMEA-002229-PIP01-17-M02

Chemo Research; Contraception / Treatment of women with polycystic ovary syndrome (PCOS) who are not seeking pregnancy / Oral contraception

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0053/2019 of 29 January 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. Ladarixin - EMEA-002642-PIP01-19-M03

Dompé farmaceutici S.p.A; Treatment of type 1 diabetes / Treatment of new-onset type 1 diabetes mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be

accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0284/2020 of 12/08/2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.9. Volanesorsen - Orphan - EMEA-001915-PIP01-15-M03

Akcea Therapeutics; Treatment of familial chylomicronemia syndrome

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The PDCO discussed this procedure at Day 30 during the February 2021 plenary meeting. Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be acceptable. The main changes relate to the definition of patient population and to the wording of the study duration.
Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0185/2020 of 13 May 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Golimumab - EMEA-000265-PIP02-11-M03

Janssen Biologics B.V.; Treatment of ulcerative colitis

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0065/2018 of 16 March 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.11. Maralixibat Chloride - Orphan - EMEA-001475-PIP02-13-M01

Mirum Pharmaceuticals; Treatment of Alagille syndrome (ALGS)

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0149/2015 issued on 10 July 2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.12. Potassium chloride / Sodium chloride / Citric acid (as citric acid anhydrous) / Sodium citrate / Simeticone / Sodium sulphate (as sodium sulfate anhydrous) / Macrogol 4000 - EMEA-001356-PIP02-12-M04

Alfasigma S.p.A.; any clinical procedures requiring a clean bowel e.g. bowel endoscopy or radiology

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0339/2020 of 9 September 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.13. Valoctocogene roxaparvovec - Orphan - EMEA-002427-PIP01-18-M01

BioMarin International Limited; Treatment of Haemophilia A

Day 60 opinion

Haematology-Hemostaseology

Summary of committee discussion:

The PDCO's view expressed at Day 30 was re-discussed and endorsed.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0218/2019 of 17 June 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.14. Upadacitinib - EMEA-001741-PIP01-14-M04

AbbVie Ltd; Treatment of Chronic Idiopathic Arthritis / Treatment of Juvenile Idiopathic Arthritis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO discussed the clarification on the timelines received from the applicant before D60.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0347/2020 of 9 September 2020).

2.3.15. Upadacitinib - EMEA-001741-PIP04-17-M02

AbbVie Ltd; Treatment of atopic dermatitis

Day 60 opinion

Immunology-Rheumatology-Transplantation / Dermatology

Summary of committee discussion:

The applicant agreed with the PDCO's request expressed at Day 30 .
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0214/2020 of 17 June 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.16. Oritavancin (diphosphate) - EMEA-001270-PIP01-12-M03

Menarini International Opernations Luxembourg S.A.; Treatment of acute bacterial skin and skin structure infections

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO re-discussed the modification following the responses received from the Applicant .
The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0131/2019 of 17 April 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.17. Tenofovir (disoproxil fumarate) - EMEA-000533-PIP01-08-M10

Gilead Sciences International Limited; Treatment of chronic viral hepatitis B

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0437/2020 of 20 November 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.18. Defatted powder of peanuts - EMEA-001734-PIP01-14-M05

Aimmune Therapeutics Inc; Peanut Allergy / Peanut oral immunotherapy for the reduction in clinical reactivity to accidental exposure in peanut children and adults

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

All issues are considered now resolved.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0114/2019 of 29 March 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.19. Dermatophagoides farinae / Dermatophagoides pteronyssinus - EMEA-001258-PIP01-11-M07

ALK-Abelló A/S; Treatment of allergic rhinitis / Treatment of asthma

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0278/2020 of 15 July 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.20. Mometasone (furoate) / Indacaterol (acetate) - EMEA-001217-PIP01-11-M07

Novartis Europharm Limited; Treatment of asthma

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that many, but not all proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0292/2018 of 12 September 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.4. Opinions on Re-examinations

No items

2.5. Opinions on Review of Granted Waivers

No items

2.6. Finalisation and adoption of opinions

No items

2.7. Partial Compliance Checks completed by EMA

For the following partial compliance checks, no need to refer them to PDCO Committee for discussion, were identified by the PME coordinator and PDCO Rapporteur. The PDCO has been informed in writing.

2.7.1. Dupilumab - EMEA-C2-001501-PIP02-13-M06

sanofi-aventis groupe; Treatment of asthma

Day 30 letter

Pneumology - Allergology

2.7.2. Pretomanid - EMEA-C1-002115-PIP01-17-M02

Global Alliance for TB Drug Development; Treatment of multi-drug-resistant tuberculosis

Day 1 letter

Infectious Diseases

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. RAAV8-hUGT1A1 - Orphan - EMEA-002021-PIP01-16

GENETHON; Treatment of Crigler-Najjar syndrome

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.2. Vedolizumab - EMEA-000645-PIP04-20

Active pouchitis (in patients who underwent proctocolectomy and ileal-pouch anal anastomosis for ulcerative colitis, familial adenomatous polyposis, and other underlying

conditions for which construction of a pouch was medically indicated), Active pouchitis (in patients who underwent proctocolectomy and ileal-pouch anal anastomosis for ulcerative colitis)

Day 90 discussion

Gastroenterology-Hepatology

3.1.3. Pegfilgrastim - EMEA-002671-PIP02-20

Treatment of chemotherapy-induced neutropenia and Prevention of chemotherapy-induced febrile neutropenia / Reduction in the duration of neutropenia and the incidence of febrile neutropenia in paediatric patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)

Day 90 discussion

Haematology-Hemostaseology

3.1.4. Human anti-interleukin-15 (IL-15) monoclonal antibody - EMEA-002775-PIP01-20

Treatment of coeliac disease

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.5. Edaravone - Orphan - EMEA-002785-PIP01-20

Treeway B.V.; Treatment of amyotrophic lateral sclerosis

Day 90 discussion

Neurology

3.1.6. EMEA-002795-PIP01-20

Prevention of lower respiratory tract disease caused by respiratory syncytial virus via maternal immunisation / Prevention of RSV-associated medically attended lower respiratory tract illness (MA-LRTI) and/or RSV associated severe MA-LRTI in neonates and infants by active immunisation of pregnant adolescents

Day 90 discussion

Vaccines

3.1.7. Ruxolitinib - EMEA-002618-PIP02-20

Vitiligo

Day 60 discussion

Dermatology

3.1.8. Single strain of non-genetically modified Prevotella histicola - EMEA-002933-PIP01-20

Treatment of psoriasis

Day 60 discussion

Dermatology

3.1.9. Glepaglutide - EMEA-002926-PIP01-20

Treatment of short bowel syndrome (SBS)

Day 60 discussion

Gastroenterology-Hepatology

3.1.10. (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one - Orphan - EMEA-002924-PIP01-20

Forma Therapeutics, Inc.; Sickle cell disease

Day 60 discussion

Haematology-Hemostaseology

3.1.11. Concizumab - Orphan - EMEA-002326-PIP04-20

Novo Nordisk A/S; Treatment of congenital haemophilia B / Treatment of congenital haemophilia A

Day 60 discussion

Haematology-Hemostaseology

3.1.12. EMEA-002927-PIP01-20

Chronic idiopathic arthritis / Treatment of juvenile idiopathic arthritis

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.13. EMEA-002928-PIP01-20

Treatment of psoriasis

Day 60 discussion

Immunology-Rheumatology-Transplantation / Dermatology / Gastroenterology-Hepatology

3.1.14. Islatravir - EMEA-002938-PIP01-20

Prevention of human immunodeficiency virus (HIV-1) infection

Day 60 discussion

Infectious Diseases

3.1.15. Branaplam - EMEA-002204-PIP02-20

Treatment of Huntington's Disease

Day 60 discussion

Neurology

3.1.16. Crisantaspase - EMEA-002934-PIP01-20

Treatment of Acute lymphoblastic leukaemia / lymphoma / Acute lymphoblastic leukaemia (ALL)/lymphoblastic lymphoma (LBL)

Day 60 discussion

Oncology

3.1.17. Loncastuximab tesirine - EMEA-002665-PIP02-20

Treatment of B-cell non-Hodgkin Lymphoma

Day 60 discussion

Oncology

3.1.18. Sepofarsen - Orphan - EMEA-002717-PIP02-20

ProQR Therapeutics; Treatment of inherited retinal disorders / Treatment of Leber congenital amaurosis due to the C2991 +1655A>G mutation in the CEP290 gene (p.Cys998X)

Day 60 discussion

Ophthalmology

3.1.19. Ligelizumab - EMEA-001811-PIP03-20

Treatment of food allergy

Day 60 discussion

Pneumology - Allergology

3.1.20. Sodium chloride solution 4.2% (w/v) / 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxamide - Orphan - EMEA-002935-PIP01-20

Parion Sciences, Inc.; Primary Ciliary Dyskinesia (PCD)

Day 60 discussion

Pneumology - Allergology

3.1.21. Matrix-M1 adjuvant / Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine (SARS CoV-2 rS) - EMEA-002941-PIP01-20

Prevention of COVID-19 caused by SARS-CoV-2 infection / Active immunisation for the prevention of mild, moderate, and severe disease caused by SARS-CoV-2 in children 6 months through 17 years of age

Day 60 discussion

Vaccines

3.1.22. Recombinant protein derived from the SARS CoV2 prefusion Spike delta TM protein adjuvanted with AS03 - EMEA-002915-PIP01-20

Prevention of Covid-19 / Prevention of Covid-19 disease / Prevention of Covid-19 infection

Day 60 discussion

Vaccines

3.1.23. EMEA-002948-PIP01-20

Treatment of dilated cardiomyopathy

Day 30 discussion

Cardiovascular Diseases

3.1.24. EMEA-002735-PIP03-20

Heart transplantation / Preservation of hearts prior to heart transplantation

Day 30 discussion

Cardiovascular Diseases

3.1.25. EMEA-002944-PIP01-20

Treatment of Type 2 Diabetes Mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.26. Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain - EMEA-002942-PIP01-20

Treatment of non-alcoholic steatohepatitis (NASH)

Day 30 discussion

Gastroenterology-Hepatology

3.1.27. Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain - EMEA-002942-PIP02-20

Treatment of obesity

Day 30 discussion

Gastroenterology-Hepatology

3.1.28. Marzeptacog alfa (activated) - Orphan - EMEA-002270-PIP03-20

Catalyst Biosciences, Inc.; Treatment of haemophilia A / Treatment of bleeding episodes in patients with congenital haemophilia A with inhibitors to Factor VIII

Day 30 discussion

Haematology-Hemostaseology

3.1.29. Marzeptacog alfa (activated) - Orphan - EMEA-002270-PIP04-20

Catalyst Biosciences, Inc.; Treatment of haemophilia B / Treatment of bleeding episodes in patients with congenital HB with inhibitors to Factor IX

Day 30 discussion

Haematology-Hemostaseology

3.1.30. Anti-CD40L humanized monoclonal antibody - EMEA-002945-PIP01-20

Treatment of Sjogren's Syndrome

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.31. Baricitinib - EMEA-001220-PIP08-20

Treatment of alopecia areata

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.32. Bamlanivimab - EMEA-002952-PIP01-21

Covid-19

Day 30 discussion

Infectious Diseases

3.1.33. Etesevimab - EMEA-002966-PIP01-21

Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.34. Exebacase - EMEA-002947-PIP01-20

Treatment of *Staphylococcus aureus* blood stream infections (bacteraemia).

Day 30 discussion

Infectious Diseases

3.1.35. Regdanvimab - EMEA-002961-PIP01-21

Treatment of Coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.36. Reparixin - Orphan - EMEA-001693-PIP02-20

Dompé farmaceutici S.p.A.; Treatment of COVID-19 pneumonia / Treatment of severe COVID-19 pneumonia

Day 30 discussion

Infectious Diseases

3.1.37. Terbinafine - EMEA-002984-PIP01-21

Treatment of onychomycosis / Treatment of distal subungual onychomycosis

Day 30 discussion

Infectious Diseases

3.1.38. EMEA-002940-PIP01-20

Treatment of COVID-19

Day 30 discussion

Infectious Diseases

3.1.39. EMEA-002943-PIP01-20

Mature B-Cell malignancies

Day 30 discussion

Oncology

3.1.40. Lutetium (177Lu) oxodotreotide - Orphan - EMEA-002950-PIP01-20

Advanced Accelerator Applications; Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) / Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adolescent patients (12 years and older)

Day 30 discussion

Oncology

3.1.41. Pembrolizumab / quavonlimab - EMEA-002949-PIP01-20

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)

Day 30 discussion

Oncology

3.1.42. Apitegromab - Orphan - EMEA-002951-PIP01-20

Scholar Rock, Inc.; Treatment of spinal muscular atrophy

Day 30 discussion

Other / Neurology

3.1.43. EMEA-002946-PIP01-20

Treatment of Major Depressive Disorder (MDD) / Rapid reduction of depressive symptoms, in conjunction with comprehensive standard of care (SoC), in adolescents with MDD who have suicidal ideation with intent

Day 30 discussion

Psychiatry

3.1.44. EMEA-002964-PIP01-21

Prophylaxis of SARS-CoV-2 infection / Treatment and decreased transmission of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.45. EMEA-002965-PIP01-21

Prophylaxis of SARS-CoV-2 infection / Treatment and decreased transmission of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

3.2.1. Simoctocog alfa - EMEA-C-001024-PIP01-10-M02

Octapharma Pharmazeutika Produktionsges.m.b.H.; Hereditary Factor VIII deficiency, Haemophilia A

Day 30 discussion

Haematology-Hemostaseology

3.2.2. Lenvatinib - EMEA-C3-001119-PIP02-12-M07

Eisai GmbH; Treatment of papillary thyroid cancer/ Treatment of follicular thyroid cancer/ Treatment of osteosarcoma

Day 30 discussion

Oncology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Pegcetacoplan - Orphan - EMEA-002600-PIP01-19-M01

Apellis Ireland Limited; Paroxysmal Nocturnal Haemoglobinuria

Day 30 discussion

3.3.2. Remimazolam (as besylate) - EMEA-001880-PIP02-19-M02

PAION Deutschland GmbH; Sedation, General Anesthesia / Sedation of mechanically ventilated patients / Sedation for short procedures

Day 30 discussion

Anaesthesiology

3.3.3. Macitentan - Orphan - EMEA-001032-PIP01-10-M03

Janssen-Cilag International NV; Treatment of systemic sclerosis / Treatment of idiopathic pulmonary fibrosis / Treatment of pulmonary arterial hypertension

Day 30 discussion

Cardiovascular Diseases

3.3.4. Ticagrelor - EMEA-000480-PIP01-08-M14

AstraZeneca AB; Prevention of thromboembolic events / Prevention of vaso-occlusive crises in paediatric patients with sickle cell disease

Day 30 discussion

Cardiovascular Diseases / Haematology-Hemostaseology

3.3.5. Spesolimab - EMEA-002475-PIP02-19-M01

Boehringer Ingelheim International GmbH; Prevention of Generalized Pustular Psoriasis / Treatment of Generalized Pustular Psoriasis

Day 30 discussion

Dermatology

3.3.6. Cipaglucosidase alfa - Orphan - EMEA-002447-PIP01-18-M01

Amicus Therapeutics Europe Limited; Treatment of glycogen storage disease Type II (Pompe's disease)

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.7. Pegunigalsidase alfa - Orphan - EMEA-001828-PIP01-15-M02

Chiesi Farmaceutici S.p.A.; Treatment of Fabry disease

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.8. Avacopan - Orphan - EMEA-002023-PIP01-16-M05

ChemoCentryx Ireland Ltd.; Treatment of anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.9. Doravirine - EMEA-001676-PIP01-14-M04

Merck Sharp & Dohme (Europe), Inc.; Treatment of human immunodeficiency virus-1 (HIV-1) infection / Antiretroviral therapy, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in children aged from birth to 18 years

Day 30 discussion

Infectious Diseases

3.3.10. Rilpivirine / Dolutegravir - EMEA-001750-PIP01-15-M04

ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus (HIV) disease

Day 30 discussion

Infectious Diseases

3.3.11. Tenofovir alafenamide / emtricitabine / cobicistat / darunavir - EMEA-001825-PIP01-15-M03

Janssen-Cilag International NV; Treatment of human immunodeficiency virus type-1 (HIV-1) infection / Treatment of HIV-1 infection in paediatric subjects weighing 25 kg or more from 6 years of age

Day 30 discussion

Infectious Diseases

3.3.12. Tenofovir disoproxil fumarate / lamivudine / doravirine - EMEA-001695-PIP01-14-M04

Merck Sharp & Dohme (Europe), Inc.; Treatment of human immunodeficiency virus-1 (HIV-1) infection / Antiretroviral combination therapy for the treatment of HIV-1 infection in adults and children aged 6 to 18 years

Day 30 discussion

Infectious Diseases

3.3.13. Ataluren - Orphan - EMEA-000115-PIP01-07-M11

PTC Therapeutics International, Limited; Treatment of dystrophinopathy / Treatment of nonsense-mutation dystrophinopathy

Day 30 discussion

Neurology

3.3.14. Brivaracetam - Orphan - EMEA-000332-PIP01-08-M16

UCB Pharma S.A.; Treatment of epilepsy with partial onset seizures / Treatment of paediatric patients with partial onset seizures

Day 30 discussion

Neurology

3.3.15. Brivaracetam - Orphan - EMEA-000332-PIP02-17-M02

UCB Pharma S.A.; Treatment of Neonatal Seizures, Treatment of paediatric epilepsy syndromes / Treatment of Neonatal Seizures with adjunctive administration of brivaracetam, Monotherapy in patients 4 to 25 years of age with Childhood Absence Epilepsy (CAE) and Juvenile Absence Epilepsy (JAE)

Day 30 discussion

Neurology

3.3.16. Bumetanide - EMEA-001303-PIP01-12-M03

Les Laboratoires Servier; Autism Spectrum Disorder / Treatment of Autism Spectrum Disorder

Day 30 discussion

Neurology

3.3.17. Ganaxolone - Orphan - EMEA-002341-PIP01-18-M01

Marinus Pharmaceuticals Inc.; Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder / Adjunctive treatment of seizures in paediatric patients aged 6 months to < 18 years old with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder

Day 30 discussion

Neurology

3.3.18. Dostarlimab - EMEA-002463-PIP01-18-M01

GlaxoSmithKline (Ireland) Limited; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies). / Treatment of paediatric patients from birth to less than 18 years old with neuroblastoma and/or osteosarcoma

Day 30 discussion

Oncology

3.3.19. Isatuximab - EMEA-002205-PIP01-17-M02

Sanofi-Aventis Recherche & Développement; Treatment of malignant neoplasms of the

haematopoietic and lymphoid tissue / Treatment of relapsed, refractory and newly-diagnosed acute myeloid leukemia in combination with standard treatment (chemotherapy) in paediatric patients from 28 days to less than 18 years of age / Treatment of relapsed, refractory and newly-diagnosed acute lymphoblastic leukemia in combination with standard treatment (chemotherapy) in paediatric patients from 28 days to less than 18 years of age

Day 30 discussion

Oncology

3.3.20. Lenvatinib - EMEA-001119-PIP03-19-M01

Eisai GmbH; Treatment of all conditions included in the category of malignant neoplasms except haematopoietic and lymphoid tissue neoplasms, papillary thyroid cancer, follicular thyroid cancer and osteosarcoma / Treatment of paediatric patients from 2 years to less than 18 years old with a relapsed or refractory solid malignant tumour including Ewing sarcoma/peripheral primitive neuroectodermal tumour, rhabdomyosarcoma and high-grade glioma

Day 30 discussion

Oncology

3.3.21. Niraparib (as tosylate monohydrate) - Orphan - EMEA-002268-PIP02-18-M01

GlaxoSmithKline (Ireland) Limited; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid malignancies) / Treatment of paediatric patients from birth to less than 18 years old with neuroblastoma and/or osteosarcoma

Day 30 discussion

Oncology

3.3.22. Obinutuzumab - Orphan - EMEA-001207-PIP01-11-M01

Roche Registration GmbH; Treatment of mature B-cell lymphoma, Treatment of acute lymphoblastic leukaemia

Day 30 discussion

Oncology

3.3.23. Ruxolitinib phosphate - EMEA-000901-PIP03-16-M02

Novartis Europharm Limited; Acute Graft versus Host Disease / Treatment of acute Graft versus Host Disease (aGvHD) in paediatric patients aged 28 days and above

Day 30 discussion

Oncology

3.3.24. Concentrate of proteolytic enzyme enriched in bromelain - Orphan - EMEA-000142-PIP02-09-M11

MediWound Germany GmbH; Treatment of burns of external body surfaces / Removal of eschar in deep partial and/or full thickness burns

Day 30 discussion

Other

3.3.25. Meloxicam / Bupivacaine - EMEA-002246-PIP01-17-M02

Heron Therapeutics B.V.; Treatment of acute postoperative pain

Day 30 discussion

Pain

3.3.26. Birch pollen extract (Betula verrucosa) - EMEA-001879-PIP01-15-M03

ALK-Abelló A/S; Treatment of allergic rhinitis / rhino-conjunctivitis / Treatment of tree pollen allergic rhinitis

Day 30 discussion

Pneumology - Allergology

3.3.27. Brexpiprazole - EMEA-001185-PIP01-11-M07

Otsuka Pharmaceutical Development & Commercialisation Europe GmbH; Treatment of schizophrenia

Day 30 discussion

Psychiatry

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 23 February 2021 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.2. Ongoing Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.3. Final Scientific Advice (Reports and Scientific Advice letters)

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. Itepekimab - EMEA-10-2020

Sanofi-aventis Recherche & Développement; All classes of medicinal products for treatment of chronic obstructive pulmonary disease (excluding chronic lung diseases associated with long-term airflow limitation, such as asthma, bronchopulmonary dysplasia, primary cilia dyskinesia, obstructive lung disease related to graft versus-host disease after [bone-

marrow] transplantation) / Add-on maintenance treatment of adult patients with chronic obstructive pulmonary disease who do not currently smoke

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: None identified at this stage.

6.1.2. Avacincaptad pegol - EMEA-11-2020

IVERIC bio, Inc.; All classes of medicinal products for treatment of age-related macular degeneration and diabetic macular oedema / Treatment of geographic atrophy secondary to dry age-related macular degeneration

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: Stargardt disease.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

No items

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

No items

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

Johannes Taminiau has been appointed member to the PDCO as the Healthcare Professional Representative by the European Commission.

Fabio Midulla has been appointed alternate to the PDCO as the Healthcare Professional Representative by the European Commission.

Tereza Bazantova has been appointed as alternate from the Czechia.

9.1.1.

9.1.2. Access to IT tools for PDCO members

Summary of committee discussion:

The PDCO Secretariat updated the committee on several IT issues affecting the committee. The PDCO Secretariat has launched an IT survey among members to evaluate if there are any members having any EMA IT tools issues and to what extent those issues are.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The PDCO members were informed about the final CHMP Opinions on 5 medicinal products with recommended paediatric indications adopted in January 2021 by CHMP. These include BroPair Spiromax and Seffalair Spiromax (salmeterol / fluticasone propionate), Keytruda (pembrolizumab), Sirturo (bedaquiline) and Vaxchora (cholera vaccine, oral, live).

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of committee discussion:

The Chair of the Non-clinical Working Group (NcWG) identified the products which will require NcWG evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.3.3. Patients and Consumers Working Party (PCWP)/ Healthcare Professionals Working Party (HCPWP)

Summary of committee discussion:

The agenda for the Patients and Consumers Working Party (PCWP)/ Healthcare Professionals Working Party (HCPWP) on 2-3 March 2021 was presented for information.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

No items

9.5. Cooperation with International Regulators

No items

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No items

9.7. PDCO work plan

No items

9.8. Planning and reporting

No items

10. Any other business

10.1. COVID -19 update

Summary of committee discussion:

The PDCO was updated on COVID vaccines and treatments.

10.2. Introduction of new Executive Director Emer Cooke

Summary of committee discussion:

Brief introduction was given by the Executive Director.

10.3.

10.4. C4C multistakeholder meeting on paediatric IBD

Summary of committee discussion:

The PDCO were informed about the upcoming multistakeholder meeting on paediatric inflammatory bowel disease.

10.5. Update on Zynteglo

EMA Paediatric Coordinator: Giovanni Lesa

Summary of committee discussion:

The PDCO was informed about the ongoing pharmacovigilance procedure.

11. Breakout sessions

11.1. Paediatric oncology

Summary of committee discussion:

The group discussed topics related to Paediatric Investigation Plans recently submitted to the PDCO.

11.2. Neonatology

Summary of committee discussion:

The neonatology breakout session was cancelled.

11.3. Internal operations

The PDCO members discussed ways to improve internal operations.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 23-26 February 2021 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Koenraad Norga	Chair	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting When not chairing the meeting: No participation in final deliberations and voting	2.3.1. Ambrisentan - Orphan - EMEA-000434-PIP01-08-M08 3.3.18. Dostarlimab - EMEA-002463-PIP01-18-M01 3.3.21. Niraparib (as tosylate monohydrate) - Orphan - EMEA-002268-PIP02-18-M01
Karl-Heinz Huemer	Member	Austria	No interests declared	
Johanna Wernsperger	Alternate	Austria	No interests declared	
Marleen Renard	Member	Belgium	No participation in discussion, final deliberations and voting on:	3.3.23. Ruxolitinib phosphate - EMEA-000901-PIP03-16-M02
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Vessela Boudinova	Alternate	Bulgaria	No interests declared	
Arnes Resic	Alternate	Croatia	No interests declared	
Georgios Savva	Member	Cyprus	No interests declared	
Elena Kaisis	Alternate	Cyprus	No interests declared	
Lucie Kravackova	Member	Czechia	No interests declared	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member (Vice-Chair)	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Dovile Zacharkiene	Member	Lithuania	No interests declared	
Silvijus Abramaviciu s	Alternate	Lithuania	No restrictions applicable to this meeting	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Martine Trauffler	Alternate (CHMP member)	Luxembourg	No interests declared	
John-Joseph Borg	Member	Malta	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Roderick Houwen	Member	Netherlands	No restrictions applicable to this meeting	
Maaike van Dartel	Alternate	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable to this meeting	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Simona Badoi	Alternate (CHMP member)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Eva Agurell	Member	Sweden	No interests declared	
Sara Vennberg	Alternate	Sweden	No interests declared	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Fabio Midulla	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Doina Plesca	Alternate	Healthcare Professionals' Representative	No interests declared	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Catherine Cornu	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jaroslav Sterba	Member	Patients' Organisation Representative	No interests declared	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Tomasz Grybek	Alternate	Patients' Organisation Representative	No interests declared	
Michal Odermarsky	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting	
María Estela Moreno Martín	Expert - via telephone*	AEMPS, Spain	No interests declared	
Lutz Wiesner	Expert - via telephone*	BfArM, Germany	No interests declared	
Mark van Bussel	Expert - in person*	CBG/MEB, Netherlands	No restrictions applicable to this meeting	
Kristin Karlsson	Expert - via telephone*	MPA, Sweden	No restrictions applicable to this meeting	
Gaby Lydia Wangorsch	Expert - via telephone*	BfArM, Germany	No interests declared	
Emmely de Vries	Expert - via telephone*	CBG/MEB, Netherlands	No interests declared	
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/